NCT04299113View on ClinicalTrials.gov

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

May 22, 2026

Study Completion Date

May 22, 2027

Conditions

Rhabdomyosarcoma

Interventions

DRUG

Vinorelbine

Given IV

DRUG

Mocetinostat

Given PO

Trial Locations (1)

90095

Rebecca Phelan, Los Angeles

Sponsors

Collaborators (1)

Mirati Therapeutics Inc.

All Listed Sponsors

collaborator

Mirati Therapeutics Inc.

INDUSTRY

collaborator

Phase One Foundation

OTHER

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT04299113 - Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | Biotech Hunter | Biotech Hunter